Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on the discovery, development, and commercialization of novel immunotherapies for the treatment of diseases that involve protein misfolding or cell adhesion. The company has market cap of $1.51 billion. It is developing antibody product candidates that include NEOD001, a monoclonal antibody that is in Phase III and Phase IIb clinical trials for the treatment of AL amyloidosis; PRX002 that has completed Phase Ib clinical trial for treating ParkinsonÂ’s disease and other related synucleinopathies; PRX003, a monoclonal antibody that is in Phase Ib for the treatment of psoriasis and other inflammatory diseases; and PRX004, a monoclonal antibody that is under preclinical development. It currently has negative earnings. The firm has a license, development, and commercialization agreement with F.
The stock of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is a huge mover today! The stock increased 3.33% or $12.75 during the last trading session, reaching $395.35. About 275,583 shares traded. Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) has risen 17.40% since January 3, 2017 and is uptrending. It has outperformed by 0.70% the S&P500.The move comes after 5 months positive chart setup for the $42.26 billion company. It was reported on Jan, 3 by Barchart.com. We have $407.21 PT which if reached, will make NASDAQ:REGN worth $1.27 billion more.
Since August 7, 2017, it had 2 insider purchases, and 8 selling transactions for $78.43 million activity. $26.67M worth of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) was sold by VAGELOS P ROY on Monday, August 21. $712,500 worth of stock was sold by BROWN MICHAEL S on Thursday, October 5. Sanofi had bought 72,378 shares worth $34.84 million. Landry Robert E sold $330,574 worth of stock or 663 shares. 2,000 shares were sold by BAKER CHARLES A, worth $900,000 on Friday, September 29.
Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, makes, and commercializes medicines for the treatment of serious medical conditions worldwide. The company has market cap of $42.26 billion. The Company’s products include EYLEA injection for the treatment of neovascular age-related macular degeneration, diabetic macular edema, and macular edema following retinal vein occlusion; Praluent injection, an adjunct to diet and tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease; and ARCALYST injection for the treatment of cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome in adults and childrenÂ’s. It has a 35.85 P/E ratio. It also markets Kevzara injection for the treatment of rheumatoid arthritis in adults; and ZALTRAP, an injection for intravenous infusion, which is used in combination with 5-fluorouracil, leucovorin, and irinotecan for the treatment of metastatic colorectal cancer.
Investors sentiment decreased to 1.17 in 2017 Q3. Its down 0.21, from 1.38 in 2017Q2. It fall, as 56 investors sold Regeneron Pharmaceuticals, Inc. shares while 165 reduced holdings. 71 funds opened positions while 187 raised stakes. 73.70 million shares or 3.04% more from 71.53 million shares in 2017Q2 were reported. Kcm Investment Advsrs Limited Liability Corporation reported 0.02% of its portfolio in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN). Campbell And Co Investment Adviser Lc, a Maryland-based fund reported 2,216 shares. Advisory Net Ltd Limited Liability Company, a Georgia-based fund reported 181 shares. First Advisors L P holds 149,311 shares or 0.17% of its portfolio. Mutual Of America Capital Mngmt Ltd Company has invested 0.07% in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN). Amer Century has invested 0.42% in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN). Tocqueville Asset Lp invested 0.05% of its portfolio in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN). World Invsts owns 6.57 million shares or 0.67% of their US portfolio. Hbk Sorce Advisory Limited Company stated it has 0.03% in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN). Keybank Association Oh holds 0.01% or 2,265 shares in its portfolio. Truenorth accumulated 5,303 shares or 1.1% of the stock. Advsr Asset Management Inc holds 0.05% in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) or 6,847 shares. Bnp Paribas Asset holds 0.01% of its portfolio in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) for 1,701 shares. Parallax Volatility Advisers Limited Partnership accumulated 3,521 shares. Jane Street Group Limited Liability Corp stated it has 33,831 shares.
Analysts await Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) to report earnings on February, 8. They expect $4.18 EPS, up 90.87% or $1.99 from last year’s $2.19 per share. REGN’s profit will be $446.79 million for 23.65 P/E if the $4.18 EPS becomes a reality. After $3.32 actual EPS reported by Regeneron Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts 25.90% EPS growth.
Among 31 analysts covering Regeneron Pharmaceuticals Inc. (NASDAQ:REGN), 13 have Buy rating, 1 Sell and 17 Hold. Therefore 42% are positive. Regeneron Pharmaceuticals Inc. has $700 highest and $300 lowest target. $502.02’s average target is 26.98% above currents $395.35 stock price. Regeneron Pharmaceuticals Inc. had 103 analyst reports since July 28, 2015 according to SRatingsIntel. The company was maintained on Thursday, September 7 by Robert W. Baird. The rating was maintained by Chardan Capital Markets on Tuesday, August 4 with “Buy”. The firm has “Equal Weight” rating by Barclays Capital given on Wednesday, August 5. The company was maintained on Thursday, September 21 by UBS. On Tuesday, June 20 the stock rating was maintained by Piper Jaffray with “Buy”. BMO Capital Markets maintained the shares of REGN in report on Tuesday, July 18 with “Hold” rating. As per Thursday, August 3, the company rating was maintained by J.P. Morgan. The firm earned “Outperform” rating on Tuesday, September 1 by Raymond James. The stock has “Hold” rating by Oppenheimer on Wednesday, September 27. Credit Suisse maintained the stock with “Buy” rating in Monday, September 11 report.
The stock increased 4.07% or $1.54 during the last trading session, reaching $39.34. About 125,868 shares traded. Prothena Corporation plc (PRTA) has risen 41.05% since January 3, 2017 and is uptrending. It has outperformed by 24.35% the S&P500.
Palo Alto Investors Llc holds 2.99% of its portfolio in Prothena Corporation plc for 1.10 million shares. Sectoral Asset Management Inc owns 195,909 shares or 1.63% of their US portfolio. Moreover, Rock Springs Capital Management Lp has 0.92% invested in the company for 309,500 shares. The Oregon-based Hood River Capital Management Llc has invested 0.82% in the stock. Oak Ridge Investments Llc, a Illinois-based fund reported 287,656 shares.
Analysts await Prothena Corporation plc (NASDAQ:PRTA) to report earnings on February, 13. They expect $-1.44 earnings per share, down 2.13% or $0.03 from last year’s $-1.41 per share. After $-1.37 actual earnings per share reported by Prothena Corporation plc for the previous quarter, Wall Street now forecasts 5.11% negative EPS growth.
Ratings analysis reveals 100% of Prothena’s analysts are positive. Out of 3 Wall Street analysts rating Prothena, 3 give it “Buy”, 0 “Sell” rating, while 0 recommend “Hold”. The lowest target is $69.0 while the high is $86.0. The stock’s average target of $76.67 is 94.89% above today’s ($39.34) share price. PRTA was included in 3 notes of analysts from December 21, 2016. The stock of Prothena Corporation plc (NASDAQ:PRTA) earned “Buy” rating by SunTrust on Wednesday, December 21. The rating was initiated by Piper Jaffray with “Overweight” on Wednesday, April 12. The stock of Prothena Corporation plc (NASDAQ:PRTA) earned “Overweight” rating by Cantor Fitzgerald on Wednesday, April 12.